Veracyte Has Released Our Inaugural ESG Report Read More
Search Open Mobile Menu
Veracyte Has Released Our Inaugural ESG Report Read More

Veracyte® Press Releases

Date Title and Summary Additional Formats
Toggle Summary Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American
View HTML
Toggle Summary Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
Data from studies encompassing over 100,000 prostate cancer patients presented at American Urology Association (AUA) 2023 Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 29, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data presented at the American Urological
View HTML
Toggle Summary Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 27, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place
View HTML
Toggle Summary New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
Findings published in European Urology Oncology suggest genomic classifier scores are highly correlated with PSMA PET upstaging of prostate cancer in those with high-risk and very high-risk disease SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 17, 2023-- Veracyte, Inc .
View HTML
Toggle Summary Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 13, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023 . Company management will host a conference call and webcast to
View HTML
Toggle Summary Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 12, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced today that seven abstracts
View HTML
Toggle Summary Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 15, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer
View HTML
Toggle Summary Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 11, 2023-- Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022 , the company had $178.9 million in cash,
View HTML
Toggle Summary Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 27, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in two upcoming investor conferences.
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
Grew Fourth Quarter Revenue to $80.3 Million Grew 2022 Total Revenue to $296.5 Million Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full
View HTML